CSF2 and neoplasm: Then, we used an anti-PD-1 antibody to prevent the binding of PD-L1 to PD-1 and found that the combination therapy with PD-1 blockade and the SA-GM-CSF-anchored vaccine synergistically induced antitumor immune responses, which greatly inhibited tumor growth, and even induced regression of established tumors.